SARS-CoV-2 Testing
Diagnostic COVID-19 Testing
Diagnostic COVID-19 Testing
PRL's labs utilizes scientific innovation and industry-leading lab automation expertise to process up to 110,000 tests per day at a low cost. We return 99% of results in < 24 hours, much faster than the industry average of 48-72 hours.
Non-Diagnostic Pooled Testing
Non-Diagnostic Pooled Testing
PRL offers pooled testing services for population surveillance.
Sequencing for Variant and Strain Detection
Sequencing for Variant and Strain Detection
PRL utilizes an integrated pipeline for direct sequencing of positive samples, including non-diagnostic whole genome sequencing, with integrated variant detection available.
Who We Serve
Who We Serve
PRL provides fast and accurate COVID-19 testing at a low cost to government agencies, health systems, labs, businesses, schools, long-term care facilities and more. As of Jan. 2022, we have performed more than 7 million SARS-CoV-2 tests since our inception.
Next generation COVID-19 testing is here
Automation
Automation
PRL integrates its parent company’s (Opentrons Labworks) laboratory automation equipment with world-renowned scientific expertise from NYU Langone to innovate laboratory processes so that samples are analyzed rapidly, accurately and massively at a scale necessary to manage the public health crisis of COVID-19.
Science
Science
PRL leverages proprietary innovations in laboratory test methodologies that provides excellent assay sensitivity, allowing us to detect COVID-19 even at the lowest levels.
Accessibility
Accessibility
PRL keeps its costs low to ensure accessibility for diagnostics in underserved communities. Our tests cost 75 percent less than the average Medicare reimbursement rate, resulting in significant healthcare cost savings for the communities we serve.
Partner with us today
FAQs
A COVID-19 PCR test utilizes reverse-transcription polymerase chain reaction (RT-PCR) to detect genetic material of SARS-CoV-2, the virus that causes COVID-19. The technology attaches short segments of DNA that detect two distinct portions of the SARS-CoV-2 genome and performs amplification over many cycles so that even small amounts of viral RNA from specimens may be detected if present. Accurate and reliable, the PCR test has been the gold standard test for diagnosing COVID-19 since authorized for use in February 2020.
PRL’s SCV2 test qualitatively detects RNA from SARS-CoV-2, the virus that causes COVID-19. Sequencing for SCV2 RNA is available on request. Visit our sequencing page for more information.
The order code is COVID19NYR.
A quote request can be submitted to the lab for pricing. Contact our team.
A minimum of 200 µL sample volume is required.
Preferred: Shipped 2°C to 8°C within 72 hours of collection Also acceptable: Ambient temperature, if received by PRL within 24 hours of collection
PRL offers SCV2 diagnostic testing, SCV2 non-diagnostic pooled testing and sequencing/variant detection.
Sensitivity (PPA)=97.4% (95% CI 91.0 – 99.3) Specificity (NPA)=100% (95% CI 92.6 - 100)
*Data from PRL NYC lab (PRL 132 PRL NYC - SCV2 Validation (ITM) Rev. 2.0 11/23/2021). Tests run in each PRL laboratory are independently developed and validated at their respective facility; performance of tests may vary.
We expect 99% of results returned in 24 hours. A separate surcharge applies if a TAT of 6 hrs is needed.
We expect 99% of results returned in 24 hours.
PRL can supply a sample collection kit, which includes sample tubes, swabs and bags, but you can use your own. PRL can provide up to 500,000 kits within two weeks to get started. PRL’s NY lab can also arrange pickups for you at $30 per pickup. Contact us for pricing at our MD & CA labs.
PRL can test for SARS-CoV-2 RNA in saliva and sample pools, as well as in nasal and nasopharyngeal swab transport media. Also acceptable are oropharyngeal (OP) swabs in transport media with nucleic acid stabilizing solution.
For STAT sequencing, samples accepted are RNA, nasopharyngeal and anterior nares swabs in viral transport media.
PRL utilizes proprietary scientific assays that can detect the presence of the SARS-CoV-2 virus in as little as 20 uL of sample while retaining gold standard industry accuracy.
The test methodology is real-time reverse transcription polymerase chain reaction (RT-PCR).
The FDA is currently evaluating PRL's emergency use authorization (EUA) application for its SCV2 test, but it has not yet received EUA for the detection of SCV2 or the diagnosis of or screening for COVID-19, and is not otherwise cleared, approved or authorized for any use by the U.S. Food and Drug Administration. The PRL SCV2 test has received authorization by the State of New York Department of Health, which will permit PRL to perform the assay in New York. Separately, the PRL SCV2 test is available as a laboratory developed test (LDT) through our Rockville, MD lab and Irvine, CA lab, serving the citizens in states and districts that have authorized PRL’s tests.
PRL uses the CDC designed RT-PCR probes and primers for the N-gene of SARS-CoV-2. To date, there have been no variants of concern/interest identified with mutations impacting these primer/probe sets. PRL runs a sequence alignment for newly identified variants to determine if there is any impact to the primer/probe set used in the assay.